4 news items
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
ARGX
BHVN
IMVT
29 May 24
-1300, Biohaven’s lead investigational drug, from its Molecular Degrader of Extracellular Proteins (MoDE) platform.
Shares plunged
What's Going On With Biohaven Stock Wednesday?
BHVN
REGN
29 May 24
on investigating a new drug. Biohaven anticipates to have Myostatin program data for Phase 3 spinal muscular atrophy in the second half of 2024.
Related
Biohaven Highlights Development And Regulatory Advances Across Therapeutic Areas And Progress Of Degrader Pipeline At 2024 Investor R&D Day
BHVN
29 May 24
Reports new interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
BHVN
29 May 24
positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular
- Prev
- 1
- Next